FBXO22 and neoplasm: F-box protein 22 (FBXO22) was found to be significantly upregulated in tumor tissues of 106 PDAC patients with poor prognosis by causing ubiquitin-dependent degradation of LATS, thus inhibiting the Hippo pathway (Ma et al., 2023).